ERBB2 and breast cancer: In this study, the activation of PI3K/AKT was due to ST6Gal1-mediated α2,6 sialylation of Human Epidermal Growth Factor Receptor 2 (HER2) (Liu et al., 2018), a breast cancer biomarker.